Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg.

Excerpt from:
Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh